Dasher Neuroscience Completes Recruitment for YA-101 Phase 2 Trial

Jul 30, 2026
Dasher Neuroscience has completed recruitment of 90 patients for a global Phase 2 trial of YA-101 in multiple system atrophy. The company expects top line clinical data in the first quarter of 2027.

Dasher Neuroscience completed patient recruitment for a global Phase 2 trial of YA-101 for multiple system atrophy, the company announced in a press release.

The trial enrolled 90 participants at clinical sites in the United States, Japan, and Taiwan. It is a global, multicenter, double blind, placebo controlled, dose escalation study evaluating safety, tolerability, pharmacokinetics, and efficacy in patients aged 30 and older with multiple system atrophy.

The primary endpoint is the frequency and severity of adverse events. Secondary endpoints include pharmacokinetic measures and clinical efficacy, assessed using the Unified Multiple System Atrophy Rating Scale and the 10 meter walk test.

Dasher said top line clinical data are expected in the first quarter of 2027. YA-101 has FDA Fast Track status and Orphan Drug status in the United States, Japan, and the European Union.

We hope you enjoyed this article

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)
Free newsletter

Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

Guide
Specialist Ambient Medical Scribe Vendors

Specialist Ambient Medical Scribe Vendors

AI scribes that turn medical consultations into draft clinical notes

Whitepaper

Tensordyne Napier: What If One Rack Could Do the Work of Nine?

Tensordyne

This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.

Read more

You may also like

Free, six days a week

Daily AI Brief: the AI news that matters, in your inbox.